London and San Francisco-based drug discovery AI startup, Causaly, has secured $60m in a series B funding round led by ICONIQ Growth. The funding will be used to expand the company’s presence in the US. Causaly utilises a combination of generative AI solutions and a best-in-class knowledge graph to enable biomedical researchers to rapidly synthesise and reference thousands of published research papers. The company claims its software can offer a 10x productivity gain for researchers, taking research that usually requires two-to-three years and completing it in two-to-three weeks. It hopes to use these methods to identify new treatments for diseases including Parkinson’s and multiple sclerosis.
Causaly secures $60M to advance AI-driven drug discovery
Date:
Frequently Asked Questions (FAQs) Related to the Above News
Please note that the FAQs provided on this page are based on the news article published. While we strive to provide accurate and up-to-date information, it is always recommended to consult relevant authorities or professionals before making any decisions or taking action based on the FAQs or the news article.
More like thisRelated
Samsung’s Foldable Phones: The Future of Smartphone Screens
Discover how Samsung's Galaxy Z Fold 6 is leading the way with innovative software & dual-screen design for the future of smartphones.
Unlocking Franchise Success: Leveraging Cognitive Biases in Sales
Unlock franchise success by leveraging cognitive biases in sales. Use psychology to craft compelling narratives and drive successful deals.
Wiz Walks Away from $23B Google Deal, Pursues IPO Instead
Wiz Walks away from $23B Google Deal in favor of pursuing IPO. Investors gear up for trading with updates on market performance and key developments.
Southern Punjab Secretariat Leads Pakistan in AI Adoption, Prominent Figures Attend Demo
Experience how South Punjab Secretariat leads Pakistan in AI adoption with a demo attended by prominent figures. Learn about their groundbreaking initiative.